Herg K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Staudacher, Ingo ^a   Jehle, Julian ^a   Staudacher, Kathrin ^a   Pledl, Hans Werner ^a,b   Lemke, Dieter ^a,b   Schweizer, Patrick A ^a   Becker, Rüdiger ^a   Katus, Hugo A ^a   Thomas, Dierk ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; DOXAZOSIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; POTASSIUM CHANNEL HERG; SMALL INTERFERING RNA; TERAZOSIN; DESIPRAMINE; ERG1 POTASSIUM CHANNEL;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; GLIOBLASTOMA; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR OCCUPANCY; TUMOR GROWTH; BRAIN TUMOR; CELL CYCLE CHECKPOINT; CELL PROTECTION; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; GENE SILENCING; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BRAIN NEOPLASMS; CASPASE 9; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYTOPROTECTION; DESIPRAMINE; DOXAZOSIN; ENZYME ACTIVATION; ETHER-A-GO-GO POTASSIUM CHANNELS; G0 PHASE; G1 PHASE; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84895559142     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088164     Document Type: Article

References (36)

1. Weller M, Cloughesy T, Perry JR, Wick W (2013) Standards of care for treatment of recurrent glioblastoma - are we there yet? Neuro Oncol 15: 4-27.
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710. (Pubitemid 350070717)
3. Assi H, Candolfi M, Baker G, Mineharu Y, Lowenstein PR, et al. (2012) Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci Lett 527: 71-77.
4. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, et al. (1999) MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97: 175-187.
5. Lacerda AE, Kramer J, Shen KZ, Thomas D, Brown AM (2001) Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J 3 (Suppl. K): K23-K30.
6. Thomas D, Gut B, Karsai S, Wimmer AB, Wu K, et al. (2003) Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn Schmiedebergs Arch Pharmacol 368: 41-48. (Pubitemid 36960483)
7. Ehrlich JR, Pourrier M, Weerapura M, Ethier N, Marmabachi AM, et al. (2004) KvLQT1 modulates the distribution and biophysical properties of HERG. A novel alpha-subunit interaction between delayed rectifier currents. J Biol Chem 279: 1233-1241. (Pubitemid 38082647)
8. Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
9. Ravens U, Cerbai E (2008) Role of potassium currents in cardiac arrhythmias. Europace 10: 1133-1137.
10. Staudacher I, Schweizer PA, Katus HA, Thomas D (2010) hERG: protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel 13: 23-30.
11. + channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn-Schmiedebergs Arch Pharmacol 383: 119-139.
12. + channels in cell proliferation and apoptosis. Cell Death Dis 2: e193.
13. González-Juanatey JR, Iglesias MJ, Alcaide C, Piñeiro R, Lago F (2003) Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade. Circulation 107: 127-131. (Pubitemid 36070944)
14. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, et al. (2004) Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn-Schmiedebergs Arch Pharmacol 369: 462-472. (Pubitemid 38669965)
15. Thomas D, Bloehs R, Koschny R, Ficker E, Sykora J, et al. (2008) Doxazosin induces apoptosis of cells expressing hERG K+ channels. Eur J Pharmacol 579: 98-103.
16. Obers S, Staudacher I, Ficker E, Dennis A, Koschny R, et al. (2010) Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedebergs Arch Pharmacol 381: 385-400.
17. Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M (1999) PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18: 3936-3943. (Pubitemid 29361331)
18. Rieger J, Lemke D, Maurer G, Weiler M, Frank B, et al. (2008) Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem 106: 2436-2448.
19. Jehle J, Staudacher I, Wiedmann F, Schweizer PA, Becker R, et al. (2012) Regulation of HL-1 cardiomyocyte apoptosis by EphA2 receptor tyrosine kinase phosphorylation and protection by lithocholic acid. Br J Pharmacol 167: 1563-1572.
20. + channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. Br J Pharmacol 168: 1215-1229.
21. Trappe K, Thomas D, Bikou O, Kelemen K, Lugenbiel P, et al. (2013) Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3 - a preclinical pilot study. Eur Heart J 34: 147-157.
22. Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188-193.
23. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, et al. (2011) Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 92: 218-225.
24. Soucek R, Thomas D, Kelemen K, Bikou O, Seyler C, et al. (2012) Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm 9: 265-272.
25. Kinch MS, Carles-Kinch K (2003) Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 20: 59-68. (Pubitemid 36308137)
26. Wykosky J, Debinski W (2008) The EphA2 receptor and EphrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 6: 1795-1806.
27. Petty A, Myshkin E, Qin H, Guo H, Miao H, et al. (2012) A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One 7: e42120.
28. Fernando MA, Heaney AP (2005) Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol 19: 3085-3096. (Pubitemid 41697723)
29. Glassmeier G, Hempel K, Wulfsen I, Bauer CK, Schumacher U, et al. (2012) Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells. Pflugers Arch 463: 365-376.
30. Thomas D, Karle CA, Kiehn J (2006) The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Design 12: 2271-2283. (Pubitemid 43891399)
31. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97: 12329-12333.
32. Frick MH, Halttunen P, Himanen P, Huttunen M, Pörsti P, et al. (1986) A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 21 (Suppl 1): 55S-62S. (Pubitemid 17170741)
33. Shionoiri H, Yasuda G, Yoshimura H, Umemura S, Miyajima E, et al. (1987) Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 10: 90-95. (Pubitemid 17106513)
34. Fawzy A, Vashi V, Chung M, Dias N, Gaffney M (1999) Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. Urology 53: 329-335. (Pubitemid 29063321)
35. Elliott HL, Meredith PA, Reid JL (1987) Pharmacokinetic overview of doxazosin. Am J Cardiol 59: 78G-81G. (Pubitemid 17085549)
36. El Harchi A, Zhang YH, Hussein L, Dempsey CE, Hancox JC (2012) Molecular determinants of hERG potassium channel inhibition by disopyramide. J Mol Cell Cardiol 52: 185-195.